The anti CD47 market is expected to reach USD 0.1 billion in 2023 and anticipated to grow at a CAGR of 42.9% during the forecast period 2021-2035.

According to the World Health Organization (WHO), cancer currently ranks as the second leading cause of death globally. Projections from the National Cancer Institute (NCI) suggest that by 2030, the United States alone might experience an influx of over 22 million new cases spanning various forms of cancer. This increasing patient population underscores a critical need for more effective treatments. Traditional approaches such as chemotherapy, surgery, and radiation, while pivotal, are often insufficient, particularly in cases of advanced cancers. Consequently, recent research efforts have pivoted toward exploring novel treatments like T-cell immunotherapies, which have exhibited promising efficacy. However, these therapies are not without limitations, often leading to off-target effects such as cytokine release syndrome and neurotoxicity. Consequently, substantial focus has been directed towards identifying drugs that can selectively target specific markers associated with cancer. Among these, CD47, identified at higher levels on cancer cells, has emerged as a significant immune checkpoint biomarker. Studies indicate that inhibiting the interaction between CD47 and SIRP? can effectively impede tumor growth and metastasis.

Presently, there are no approved therapies specifically targeting the CD47/SIRP? pathway for advanced cancers like myelodysplastic syndromes (MDS), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). Worldwide, researchers and developers are assessing drugs with dual capabilities, aiming to heighten efficacy and broaden the spectrum of targeted options. These candidate treatments seek to address biomarkers such as HER2, PD-L1, CD-38, CD-40, and CD-20 in conjunction with CD47. While many of these candidates are in their nascent stages of clinical development, developers express optimism about their therapeutic potential. The escalating number of research publications, patents, and ongoing clinical trials in this domain further substantiates the viability of anti-CD47 therapeutics in combating various cancers. Anticipations suggest significant growth in the market for these treatments, offering an advantageous position to pioneers in this evolving field


Report Coverage
? The report conducts an analysis of the Anti-CD47 market, focusing on disease indications, molecule types, prominent market players, and key geographical regions.
? Examination of market growth drivers, restraints, opportunities, and challenges to provide a comprehensive understanding of factors influencing market dynamics.
? Assessment of potential advantages and barriers within the market, accompanied by insights into the competitive landscape among leading market players.
? Forecasting of market segment revenues across various countries for strategic insights.
? Detailed survey of the current landscape of CD47 targeting therapeutics, encompassing developmental phases, targeted diseases, therapeutic areas, molecule types, therapy modalities, biologic classifications, administration routes, and special drug designations. Additionally, comprehensive information on involved companies, establishment details, employee count, and headquarters location.
? In-depth profiles of key players in CD47 therapeutics development, including company overviews, drug candidates, financial information where available, recent progress, and future prospects.
? Analysis of completed, ongoing, and planned clinical trials for CD47 targeting therapies considering parameters such as registration year, patient enrollment, trial phases, recruitment status, leading sponsors, organizations involved, therapeutic areas, and geographical distribution.
? Review of nearly 600 scientific articles on CD47 targeting therapies based on publication year, types, therapeutic areas, target indications, and major publishing journals.
? Examination of partnerships formed between entities engaged in CD47 targeting therapies from 2016 to 2021, focusing on instances, types, geographical distribution, and active participants.
? Analysis of investment activities (venture capital, debt financing, grants, IPOs) in companies involved in anti-CD47 drugs between 2016 and 2021.
? Identification and assessment of key opinion leaders (KOLs) in the anti-CD47 drugs market based on their involvement in clinical studies and geographical mapping.
? Analysis of Twitter trends related to CD47 therapies, including popular accounts, keywords, hashtags, year-wise trends, and industry player engagement.
? Presentation of a 3-D bubble chart analysis of companies in the anti-CD47 drugs market across North America, Europe, and Asia-Pacific based on pipeline strength, portfolio diversity, and portfolio strength.
? Creation of a wind rose chart highlighting major pharmaceutical players involved in anti-CD47 drugs, showcasing parameters like therapeutics under development, phase of development, line of therapy, indications targeted, and experience years.
? Evaluation of startups established between 2011 and 2020 with fewer than 200 employees engaged in CD47 therapeutics development, focusing on parameters such as development phase, indications targeted, funding, investors, funding type, and deals made.

Key Market Companies
? Abpro
? ALX Oncology
? Apmonia Therapeutics
? Arch Oncology
? Aurigene
? Bristol Myers Squibb
? EpicentRx
? Forty Seven
? ImmuneOncia Therapeutics
? ImmuneOnco Biopharmaceuticals
? Innovent Biologics
? KAHR Medical
? Light Chain Bioscience
? Morphiex
? Trillium Therapeutics